Paysign, Inc. (NASDAQ:PAYS – Get Free Report) insider Matthew Louis Lanford sold 25,360 shares of the stock in a transaction on Friday, November 8th. The stock was sold at an average price of $3.96, for a total value of $100,425.60. Following the completion of the transaction, the insider now owns 109,731 shares of the company’s stock, valued at $434,534.76. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.
Paysign Stock Performance
Shares of PAYS stock opened at $3.68 on Thursday. The stock has a fifty day moving average price of $3.96 and a 200 day moving average price of $4.34. The stock has a market cap of $197.06 million, a PE ratio of 24.53 and a beta of 0.95. Paysign, Inc. has a 1 year low of $2.22 and a 1 year high of $5.59.
Paysign (NASDAQ:PAYS – Get Free Report) last announced its quarterly earnings results on Tuesday, November 5th. The company reported $0.03 earnings per share for the quarter, beating analysts’ consensus estimates of $0.01 by $0.02. Paysign had a return on equity of 30.64% and a net margin of 14.28%. The business had revenue of $15.26 million during the quarter, compared to analysts’ expectations of $14.96 million. During the same quarter last year, the business posted $0.02 earnings per share. As a group, equities research analysts predict that Paysign, Inc. will post 0.21 earnings per share for the current year.
Hedge Funds Weigh In On Paysign
Wall Street Analysts Forecast Growth
Separately, Barrington Research restated an “outperform” rating and set a $7.00 target price on shares of Paysign in a research report on Monday, November 4th.
Check Out Our Latest Research Report on Paysign
About Paysign
Paysign, Inc provides prepaid card programs, comprehensive patient affordability offerings, digital banking services, and integrated payment processing services for businesses, consumers, and government institutions. Its product offerings include solutions for corporate rewards, prepaid gift cards, general purpose reloadable debit cards, employee incentives, consumer rebates, donor compensation, clinical trials, healthcare reimbursement payments and pharmaceutical payment assistance, and demand deposit accounts accessible with a debit card.
Further Reading
- Five stocks we like better than Paysign
- How to Find Undervalued Stocks
- Shopify Stock Rally Continues: Why the Growth Story Isn’t Over
- Profitably Trade Stocks at 52-Week Highs
- Tariff Troubles: 3 Stocks Planning Higher Prices
- Basic Materials Stocks Investing
- Mercer Near Rock Bottom: Is This High-Yield Play Set to Soar?
Receive News & Ratings for Paysign Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paysign and related companies with MarketBeat.com's FREE daily email newsletter.